A Cochrane network meta-analysis of 160 randomized clinical trials including 57,611 patients with moderate to severe plaque psoriasis found that biologic therapies, particularly interleukin (IL)-17 and IL-23 inhibitors, were associated with the highest likelihood of achieving PASI 90 during the 8- to 24-week induction period, with no meaningful differences in serious adverse events compared with placebo. Oral systemic therapies demonstrated lower efficacy but remain relevant options, while differences in onset and durability between biologic classes may influence treatment selection and interpretation of short-term outcomes.